The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Side-effect management › BRAF/MEK inhibitors and statins › Reply To: BRAF/MEK inhibitors and statins
December 11, 2017 at 1:57 am #4527
Expert NurseKathleen Madden
Regarding your adjuvant patient who is experiencing ongoing colitis despite 3 doses of infliximab,vedolizumab would have been a good next step consideration, unfortunately, this is not an option. Just a thought, could the patient be treated on a routine “colitis” regimen with maintenance dosing rather than episodic dosing until sx are under long term control. Thoughts?